Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: All that glitters is not gold
- PMID: 36323356
- DOI: 10.1016/j.jhep.2022.10.018
Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: All that glitters is not gold
Keywords: Immune Checkpoint Inhibitors; Liver cancer; competing risk; objective response; overall survival; prognosis; progression free survival; surrogacy; tyrosine kinase inhibitors.
Comment on
-
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.J Hepatol. 2023 Jan;78(1):133-141. doi: 10.1016/j.jhep.2022.09.006. Epub 2022 Sep 20. J Hepatol. 2023. PMID: 36341767 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical